TORONTO, Nov. 14, 2025 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm” or “Company“), a pharmaceutical company specializing in precision cannabinoids, today announced that the Ontario Superior Court of Justice (Commercial List) (“Court“) completely rejected the claim (CV-25-00742450-0000) (“Demand“), issued by Apollo Technology Capital Corporation (“Apollo“), Nobul Technologies Inc. (“Nobul“), and Regan McGee (along with Apollo and Nobul, “Plaintiffs“) on May 5, 2025 against MediPharm CEO David Pidduck and Chairman Chris Toews.
Further to the Company's press release dated May 28, 2025, in which the Company announced that Plaintiffs have agreed to dismiss a frivolous $50 million conflict of interest claim against the Company's trial counsel, based entirely on the principle of lack of bias (“Waiver of trial May 2025“), MediPharm is pleased to announce that the Court has granted the anti-SLAPP motion filed by Mr. Pidduk and Mr. Toews pursuant to the anti-SLAPP provisions of Section 137.1(3). Law on courts (Ontario) (“Movement“), completely dismissing the remaining libel charges against them.
The plaintiffs, among other things, sought damages of $50 million against Mr. Pidduck and Mr. Toews for defamation in connection with a letter that was sent to a former executive of a MediPharm subsidiary operating with Apollo on April 29, 2025 (“Letter dated April 29“), in connection with a challenge to the powers of attorney initiated by the Plaintiffs. In deciding to grant the Motion and dismiss all other aspects of the Claim in its entirety, the Court noted the following:
“I believe that the letter dated April 29 is typical of a letter from a lawyer that would be expected in such circumstances.”
“In my view, there is sufficient evidence to support the truth of the allegations/concerns contained in the April 29 letter and, again, there is no evidence to the contrary.”
“I find that plaintiffs have completely failed to meet their burden, and I find that defendants have generally established valid defenses to each of the four defenses they assert.”
“Plaintiffs have presented no evidence that the April 29 letter caused any harm, let alone the 'serious harm' they must prove under Section 137.1(4)(b).”
The Court's successful application today follows both the Court's dismissal in May 2025 and the Court's subsequent dismissal of an application filed by Apollo and Nobul against the Company on May 16, 2025 relating to, among other things, the appointment of an independent third party chairman to preside over the Company's annual and special meeting of shareholders on June 16, 2025 (“Application“). The costs due to MediPharm as a result of the complete rejection of the Application have not yet been paid by Apollo and Nobul.
MediPharm also wishes to alert its shareholders that certain prior press releases relating to Apollo were modified and distributed on behalf of the company and/or posted on its SEDAR+ profile without its permission and consent on Friday, November 7, 2025 and Monday, November 10.th2025 (“Unauthorized press releases“). Unauthorized press releases refer to press releases previously disseminated by the Company on May 13, 2025 and May 15, 2025 (“Current press releasesMediPharm is actively working with the appropriate third party press release distribution platform to address this issue.
ABOUT MediPharm Laboratories
Founded in 2015, MediPharm Labs specializes in the development and production of pharmaceutical grade purified cannabis concentrates, active pharmaceutical ingredients (APIs) and advanced derivative products in a GMP certified facility and ISO cleanrooms. MediPharm Labs has invested in an expert, research-based team, state-of-the-art technology, post-purification methodologies and purpose-built facilities to deliver pure, reliable and precisely dosed cannabis products to its customers. MediPharm Labs designs, develops, processes, packages and distributes cannabis and advanced cannabinoid products to domestic and international medical markets.
In 2021, MediPharm Labs received a pharmaceutical manufacturing license from Health Canada, becoming the only company in North America with a domestic commercial-scale Good Manufacturing Practices license to extract multiple naturally occurring cannabinoids. This GMP license was the first step in registering the company's current overseas drug manufacturing facility with the US FDA.
In 2023, MediPharm acquired VIVO Cannabis Inc., which expanded MediPharm's reach to medical patients in Canada through the medical e-commerce platform Canna Farms, and in Australia and Germany through Beacon Medical Australia PTY Ltd. and Beacon Medical Germany GMBH. The acquisition also included Harvest Medical Clinics in Canada, which provides medical cannabis patients with physician consultations for medical cannabis education and prescriptions.
The Company operates in compliance with all applicable laws of the countries in which it operates.
Website: www.medipharmlabs.com
Investor contact person:
MediPharm Labs Investor Relations
Phone: +1 416.913.7425
E-mail: [email protected]
Cautionary Note Regarding Forward-Looking Information:
This press release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as of the date of this press release. Any statement that includes a discussion of projections, expectations, beliefs, plans, projections, goals, assumptions, future events or results (often, but not always, using phrases such as “expects” or “does not expect,” “expects,” “anticipates” or “does not expect,” “plans,” “budget,” “scheduled,” “predicts,” “estimates,” “believes,” or “intends,” or variations of such words and phrases, or states that Certain actions, events or results “may” or “could”, “might” or “will” occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking statements in this press release relate to, among other things, the costs that MediPharm will be required to pay in connection with the denial of the Application. Forward-looking statements are necessarily based on a number of estimates and assumptions that, while believed to be reasonable, are subject to known and unknown risks, uncertainties and other factors that may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; MediPharm Labs' inability to obtain adequate financing; delay or failure to obtain regulatory approvals; and other factors discussed in MediPharm Labs' continuous disclosure filings available on SEDAR+ at www.sedarplus.ca. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this press release. Except as required by law, MediPharm Labs does not undertake any obligation to update forward-looking statements, beliefs, opinions, forecasts or other factors if they change.
